Bodytechmed Signs Marketing and Distribution Agreement for In Vitro Diagnostic Products Targeting North American Market

Choi Eui-yeol, CEO of Boditech Med (left), and Robert Mattachion, Chairman and CEO of NOVO Integrated Sciences, signed an MOU for marketing and distribution partnership of Boditech Med's point-of-care diagnostic products.

[Asia Economy Reporter Lee Gwan-joo] Boditech Med announced on the 1st that it has launched in vitro diagnostic solutions and technologies with NOVO Integrated Sciences (NOVO), a provider of primary healthcare services and wellness products in the United States and Canada, and signed a partnership for marketing and distribution.

NOVO is a Nevada-based U.S. company with subsidiaries in Canada and the United States. It is a Nasdaq-listed company offering multidisciplinary primary care-related services and products through the integration of medical technology, advanced therapies, and rehabilitation sciences.

Following a recent memorandum of understanding to establish a corporation and build production facilities for on-site diagnostic products in Florida, Boditech Med plans to accelerate its entry into the North American in vitro diagnostics market by signing a marketing and distribution partnership with NOVO.

Boditech Med aims to expand sales in the U.S. after receiving FDA approval for more than 70 biomarker products currently sold in 120 countries.

CEO Choi Eui-yeol stated, “Diagnostic tests remain a critical issue for patients in North America, with high demand for diagnostic products that provide quick results at reasonable costs. Through the partnership with NOVO, our marketing and distribution partner, we will achieve meaningful results in the North American region.”